A 2026 review reported a testosterone difference with ashwagandha. Understand the evidence limits, wellbeing findings and implications for clinical care.
On February 25, 2026, Planta Medica electronically published Fornalik and colleagues’ systematic review and meta-analysis of oral ashwagandha and circulating hormones in adults. The paper examined randomized trials rather than introducing a clinical treatment guideline.
This article is for informational purposes only and is not medical advice. Decisions about symptoms, supplement use or testosterone treatment belong with a qualified clinician.
Fornalik and colleagues’ meta-analysis included 23 randomized, placebo-controlled trials and 1,706 participants overall. It examined circulating hormone levels across the included adult populations. Those figures describe the full review rather than a testosterone-only analysis in men.
The reported average testosterone difference in men taking ashwagandha was 57.43 ng/dL compared with placebo. For women, the estimate was 5.09 ng/dL. The researchers reported a significant difference between genders.
That result is a comparison between treatment groups. It is not a prediction that every man taking ashwagandha will experience the same change. A pooled average answers a research question about the participants studied rather than supplying a personal forecast.
The authors concluded that ashwagandha may affect hormonal pathways involving cortisol and sex hormones. This makes the review relevant to hormone research. It does not turn the paper into guidance for treating testosterone deficiency.
The most useful reading separates the measured outcome from the outcome a reader hopes for. A testosterone finding concerns a blood-test result. Better energy, sexual wellbeing and physical performance are different outcomes that need evidence of their own.
This distinction matters when interpreting supplement claims. A statement about a measured hormone difference can accurately describe a study while still leaving the reader’s main question unanswered: did participants experience a worthwhile benefit?
A commercial supplement review published on October 19, 2026 summarized an Australian trial from 2019. That trial involved 57 overweight men aged 40 to 70. Participants taking a root-and-leaf ashwagandha extract over eight weeks had a 14.7% greater testosterone increase than those taking placebo.
The same review reports no significant difference from placebo in fatigue, vigor or sexual wellbeing. It also says testosterone remained within the normal range. The hormone result and the reported wellbeing results therefore told different parts of the story.
This is the clearest example in the supplied evidence of why the choice of outcome matters. Someone researching persistent tiredness may care most about fatigue. Someone concerned about sexual wellbeing may be looking for a change in that experience rather than a different laboratory number.
For those questions, the trial’s symptom findings deserve attention alongside its testosterone finding. Reporting only the percentage change would leave out information directly relevant to why many men consider a supplement in the first place.
There is also an important distinction between “no significant difference” and proof that an effect is impossible. The trial did not demonstrate an advantage on those wellbeing measures. Its results should be described at that level rather than converted into a universal claim about all men.
The practical reading is straightforward: keep the hormone outcome and the wellbeing outcomes next to each other. Neither should disappear from the account because the other makes a more appealing headline. That produces a more useful summary than treating a laboratory change as the entire result.
The central limitations concern the reporting of the pooled estimate and the scope of the underlying trials. Each affects how confidently the findings can be applied outside the research setting.
The meta-analysis abstract does not provide several details for the male testosterone result:
These omissions prevent a close assessment of the estimate’s precision and consistency from the abstract alone. Heterogeneity refers to differences across studies. The authors themselves identify heterogeneity and limited data for some hormone outcomes as reasons for further standardized trials.
The appropriate conclusion is therefore narrower than “a precise and consistent effect has been established.” The review reports a testosterone signal that warrants further investigation. Its authors’ call for standardized research is part of the finding’s interpretation rather than a minor footnote.
The commercial review describes the 2019 trial’s evidence as low certainty. That assessment belongs to the trial being discussed. It should not be presented as a formal certainty rating for the entire 2026 meta-analysis.
Its population also matters. The participants were overweight men in a defined age group whose testosterone reportedly remained within the normal range. That is not the same clinical situation as established hypogonadism.
The review says many of the men’s trials it discusses lasted 8 to 12 weeks and enrolled fewer than 60 men. These are short and small studies. Their results should not be stretched into claims about sustained benefits over longer periods.
According to the commercial review, extracts in many of the trials were supplied or funded by manufacturers. That involvement is relevant when weighing early findings. It does not by itself show that a result is wrong.
It does mean that study design and complete outcome reporting deserve close attention. The important question is whether the evidence supports the specific claim being made. A favorable hormone result does not remove the need to examine less favorable or unchanged outcomes.
The older trial is also being discussed here through a commercial review rather than quoted directly from its original report. That distinction should remain visible. A vendor’s interpretation is not an independent clinical recommendation.
For broader context on how these questions fit together, Testostra’s longer assessment of ashwagandha research addresses the evidence and its boundaries. The useful next question is not simply whether a supplement changes a number. It is whether the available research supports the benefit being claimed for a relevant population.
The bottom line is that this evidence does not justify an immediate change in current medical practice. It adds to research on ashwagandha and circulating hormones. It does not establish ashwagandha as a treatment for low testosterone or replace the diagnostic process used in clinical care.
The European Association of Urology guideline provides the relevant clinical reference point. It calls for compatible symptoms or signs alongside consistently low morning testosterone on at least two separate occasions. It specifies fasting measurements using a reliable assay.
The guideline’s recommended sampling window is between 07:00 and 10:00. It also calls for confirmation before testosterone therapy begins. These are diagnostic recommendations from the guideline rather than a supplement-testing protocol or an instruction for an individual reader.
A pooled supplement result and a clinical diagnosis serve different purposes. The former describes a comparison within research. The latter brings symptoms and properly obtained laboratory findings together to assess a particular person.
For men trying to understand that distinction, the useful clinical conversation is about the concern itself and the evidence needed to assess it. A supplement headline should not decide the explanation for tiredness or sexual changes. Testostra’s discussion of symptoms alongside hormone testing provides related educational context.
When assessing a claim about this review, several questions keep the discussion focused:
These questions do not diagnose a condition or select a treatment. They help keep the interpretation aligned with the evidence. A related explanation of why a laboratory result needs clinical context develops that distinction further.
The clinical position remains measured: acknowledge the reported hormone finding without assigning it a treatment role the evidence has not established. Personal decisions about persistent symptoms or possible testosterone deficiency still require qualified assessment rather than a supplement-based shortcut.
Assessing ashwagandha claims in an individual man’s care belongs with his clinician; Testostra contributes clear explanations of the research. The gap between a higher testosterone result and a meaningful health benefit is the issue: its evidence-led hormone education helps men separate study findings from supplement marketing and social-media claims.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra